Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Multivalent Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

NCT05289037
View directory record Official record
Conditions
COVID-19
Interventions
AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 2, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT05823974
View directory record Official record
Conditions
Influenza, Human
Interventions
F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 2, 2026, 7:28 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Trials of Multivalent Opioid Vaccine Components

NCT04458545
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Oxy(Gly)4-sKLH vaccine - Low Dose, Oxy(Gly)4-sKLH vaccine - High Dose, Placebo Oxy(Gly)4-sKLH vaccine
Biological
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

NCT00579423
View directory record Official record
Conditions
Prostate, Cancer
Interventions
QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

NCT03769194
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

NCT03583606
View directory record Official record
Conditions
Ebola Disease, Immunisation
Interventions
ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00004052
View directory record Official record
Conditions
Leukemia
Interventions
QS21, bcr-abl peptide vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

NCT05004181
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions
BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
14
States / cities
Long Beach, California • San Diego, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
aldesleukin, allogeneic large multivalent immunogen vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

NCT06182124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC), Licensed pneumococcal comparator vaccine, Multivalent Pneumococcal Vaccine - Formulation 3, Multivalent Pneumococcal Vaccine - Formulation 4
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
20
States / cities
Doral, Florida • Hialeah, Florida • Stockbridge, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

NCT03970733
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

NCT02860650
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

NCT06531538
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Months to 15 Months
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
35
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Lake Forest, California • Walnut Creek, California • Milford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

NCT02891980
View directory record Official record
Conditions
Ebola Disease, Marburg Disease
Interventions
Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 2, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

NCT05988203
View directory record Official record
Conditions
Monkeypox
Interventions
BNT166a
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
San Diego, California • Kansas City, Missouri • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 7:28 PM EDT